2 completed, 1 active not recruiting, 1 terminated. 4 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of HRS-3095 in Healthy Volunteers HRS-3095 - Chronic Spontaneous Urticaria | Early Phase 1 | Active not recruiting | Atridia Pty Ltd. | 36 | 2026-07-27 | 2026-10-30 |
| Mepolizumab for the Treatment of Chronic Spontaneous Urticaria Nucala - Chronic Spontaneous Urticaria | Early Phase 1 | Completed | Mayo Clinic | 10 | 2019-07-30 | 2025-08-27 |
| Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria Autologous mesenchymal stem cell - Urticaria, Autoimmune Diseases | Early Phase 1 | Completed | Manisa Celal Bayar University | 10 | 2017-03-03 | 2018-07-18 |
| Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor M5, C1-inhibitor - Acute Ischemic Stroke | Early Phase 1 | Terminated | TSI, LLC | 8 | 2012-09-01 | 2021-01-19 |
Chronic Urticaria (3) · Angioedemas, Hereditary (1) · Autoimmune Diseases (1) · Brain Infarction (1) · Brain Ischemia (1) · Cardiovascular Diseases (1) · Cerebral Infarction (1) · Cerebrovascular Disorders (1) · Immune System Diseases (1) · Ischemia (1) · Ischemic Stroke (1) · Skin Diseases (1) · Stroke (1) · Vascular Diseases (1)
Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Skin Diseases, Vascular (4) · Skin and Connective Tissue Diseases (4) · Chronic Disease (3) · Disease Attributes (3) · Immune System Diseases (3) · Skin Diseases (3) · Angioedema (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
Complement C1 Inhibitor Protein (1) · mepolizumab (1)
Atridia Pty Ltd. (1) · Manisa Celal Bayar University (1) · Mayo Clinic (1) · TSI, LLC (1)
Australia (1) · Netherlands (1) · Turkey (Türkiye) (1) · United States (1)